RecruitingNCT07531693
Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer
Patient Relevant Outcomes Improvement Program in High Risk HR-positive Breast Cancer
Sponsor
Institut fuer Frauengesundheit
Enrollment
200 participants
Start Date
Feb 19, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
The goal of this observational study is to evaluate how persistently patients with high-risk early breast cancer take abemaciclib 6 months after therapy start. To this end, researchers will perform a retrospective analysis of therapy data.
Eligibility
Sex: FEMALEMin Age: 18 Years
Inclusion Criteria4
- Femal patients age 18 or older at time of informed consent
- Confirmed diagnosis of HR+/HER2- early breast cancer (no distant metastasis)
- Prescribed abemaciclib therapy according to the Summary of Product Characteristics (SmPC)
- Abemaciclib therapy occured between January 1st, 2023 and June 30th, 2025
Exclusion Criteria3
- Locally advanced or metastatic breast cancer
- Male patients
- Patients with contraindication(s) for abemaciclib therapy according to SmPC
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07531693
Related Trials
A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer
NCT071620511 location
RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia
NCT067975312 locations